Depressive Syndromes in Autoimmune Disorders of the Nervous System: Prevalence, Etiology, and Influence

Yanjun Liu, Xiangqi Tang, Yanjun Liu, Xiangqi Tang

Abstract

Autoimmune diseases of the nervous system (ADNS) consist of a group of severely disabling disorders characterized by abnormal immune attack against protein components of the nervous system. This type of attack behavior may occur in the central or peripheral nervous system, and in the neuromuscular junction, resulting in neuronal damage, axonal injury, demyelination or destruction of the neuromuscular junction. While the neurological deficits of patients with ADNS have received significant research attention, the manifestation of depression tends to be ignored. In fact, depressive manifestation is common in ADNS and adds significant burden upon patients suffering from this disease. Here, we systematically reviewed the current literature to highlight the prevalence, etiology and influence of depressive manifestation in ADNS. Most autoimmune diseases of the nervous system are discussed in this paper, from multiple sclerosis, acute disseminated encephalomyelitis and autoimmune encephalitis to acute myelitis, neuromyelitis optica, Guillain-Barré syndrome and myasthenia gravis. Depressive symptoms usually develop as a comorbidity during the course of disease, but sometimes exist as a primary presentation of the disease. Psychosocial factors, long periods of disablement and chronic pain are the three most common causes of depressive symptoms in many chronic conditions, particularly in peripheral neuropathy. Furthermore, the higher prevalence of depressive symptoms in ADNS suggests that immunological dysregulation may contribute to the elevated morbidity of depression. Finally, structural lesions of the brain, and some medications for ADNS, are also thought to precipitate depressive states in ADNS.

Keywords: anxiety; autoimmunity; depression; etiology; nervous system disorder.

References

    1. Chang T. Friendly fire on neurons: antibody-mediated diseases of the nervous system. Ceylon Med J. (2015) 60:121–5. 10.4038/cmj.v60i4.8218
    1. Wildemann B, Jarius S. The expanding range of autoimmune disorders of the nervous system. Lancet Neurol. (2013) 12:22–4. 10.1016/S1474-4422(12)70301-0
    1. Tiller JWG. Depression and anxiety. Med J Aust. (2012) 1:28–31. 10.5694/mjao12.10628
    1. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord. (2008) 23:183–9. 10.1002/mds.21803
    1. Schulte-Altedorneburg M, Bereczki D. Post-stroke depression. Orv Hetil. (2014) 155:1335–43. 10.1556/OH.2014.29968
    1. Chi S, Wang C, Jiang T, Zhu X-C, Yu J-T, Tan L. The prevalence of depression in Alzheimer's disease: a systematic review and meta-analysis. Curr Alzheimer Res. (2015) 12:189–98. 10.2174/1567205012666150204124310
    1. Nowak G, Kubera M, Maes M. Neuroimmunological aspects of the alterations in zinc homeostasis in the pathophysiology and treatment of depression. Acta Neuropsychiatr. (2000) 12:49–53. 10.1017/S0924270800035705
    1. Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg. (2002) 104:182–91. 10.1016/S0303-8467(02)00036-7
    1. Feinstein A, Magalhaes S, Richard J-F, Audet B, Moore C. The link between multiple sclerosis and depression. Nat Rev Neurol. (2014) 10:507–17. 10.1038/nrneurol.2014.139
    1. Boeschoten RE, Braamse AM, Beekman AT, Cuijpers P, van Oppen P, Dekker J, et al. . Prevalence of depression and anxiety in multiple sclerosis: a systematic review and meta-analysis. J Neurol Sci. (2017) 372:331–41. 10.1016/j.jns.2016.11.067
    1. Wilkening A, Haltenhof H. Mental disorders associated with multiple sclerosis. Dtsch Med Wochenschr. (2006) 131:154–8. 10.1055/s-2006-924938
    1. Thielscher C, Thielscher S, Kostev K. The risk of developing depression when suffering from neurological diseases. Ger Med Sci. (2013) 11:Doc02. 10.3205/000170
    1. Byatt N, Rothschild AJ, Riskind P, Ionete C, Hunt AT. Relationships between multiple sclerosis and depression. J Neuropsychiatry Clin Neurosci. (2011) 23:198–200. 10.1176/jnp.23.2.jnp198
    1. Zorzon M, de Masi R, Nasuelli D, Ukmar M, Mucelli RP, Cazzato G, et al. . Depression and anxiety in multiple sclerosis. A clinical and MRI study in 95 subjects. J Neurol. (2001) 248:416–21. 10.1007/s004150170184
    1. Hellmann-Regen J, Piber D, Hinkelmann K, Gold SM, Heesen C, Spitzer C, et al. . Depressive syndromes in neurological disorders. Eur Arch Psychiatry Clin Neurosci. (2013) 263:123–36. 10.1007/s00406-013-0448-6
    1. Marrie RA, Reingold S, Cohen J, Stuve O, Trojano M, Sorensen PS, et al. . The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. Mult Scler J. (2015) 21:305–17. 10.1177/1352458514564487
    1. Parrish JB, Weinstock-Guttman B, Smerbeck A, Benedict RHB, Yeh EA. Fatigue and depression in children with demyelinating disorders. J Child Neurol. (2013) 28:713–8. 10.1177/0883073812450750
    1. Boeschoten RE, Schaakxs R, Dekker J, Uitdehaag BMJ, Beekman ATF, Smit JH, et al. . Does the presence of multiple sclerosis impact on symptom profile in depressed patients? J Psychosom Res. (2017) 103:70–6. 10.1016/j.jpsychores.2017.10.006
    1. Har-Gil M, Evrani M, Watemberg N. Torticollis as the only manifestation of acute disseminated encephalomyelitis. J Child Neurol. (2010) 25:1415–8. 10.1177/0883073810368995
    1. Granerod J, Ambrose HE, Davies NWS, Clewley JP, Walsh AL, Morgan D, et al. . Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis. (2010) 10:835–44. 10.1016/S1473-3099(10)70222-X
    1. Gray MP, Gorelick MH. Acute disseminated encephalomyelitis. Pediatr Emerg Care (2016) 32:395–400. 10.1097/PEC.0000000000000825
    1. Matsuda M, Miki J, Tabata K-I, Ikeda S-I. Severe depression as an initial symptom in an elderly patient with acute disseminated encephalomyelitis. Int Med. (2001) 40:1149–53. 10.2169/internalmedicine.40.1149
    1. Habek M, Brinar M, Brinar VV, Poser CM. Psychiatric manifestations of multiple sclerosis and acute disseminated encephalomyelitis. Clin Neurol Neurosurg. (2006) 108:290–4. 10.1016/j.clineuro.2005.11.024
    1. Krishnakumar P, Jayakrishnan M, Devarajan E. Acute disseminated encephalomyelitis presenting as depressive episode. Indian J Psychiatry (2011) 53:367. 10.4103/0019-5545.91913
    1. Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. . A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. (2016) 15:391–404. 10.1016/S1474-4422(15)00401-9
    1. Kayser MS, Dalmau J. The emerging link between autoimmune disorders and neuropsychiatric disease. J Neuropsychiatry Clin Neurosci. (2011) 23:90–7. 10.1176/appi.neuropsych.23.1.90
    1. Yaluð* I, Alemdar M, Tufan AE, Kirmizi-Alsan E, Kutlu H. Limbic encephalitis presenting with anxiety and depression: a comprehensive neuropsychological formulation. World J Biol Psychiatry (2009) 10:616–9. 10.1080/15622970701829681
    1. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. . Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. (2008) 7:1091–8. 10.1016/S1474-4422(08)70224-2
    1. Tüzün E, Zhou L, Baehring JM, Bannykh S, Rosenfeld MR, Dalmau J. Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. Acta Neuropathol. (2009) 118:737. 10.1007/s00401-009-0582-4
    1. Alper G. Acquired Demyelinating and Other Autoimmune Disorders of the Central Nervous System in Children. Los Angeles, CA: SAGE Publications Sage CA; (2012).
    1. Chanson JB, Zephir H, Collongues N, Outteryck O, Blanc F, Fleury M, et al. . Evaluation of health-related quality of life, fatigue and depression in neuromyelitis optica. Eur J Neurol. (2011) 18:836–41. 10.1111/j.1468-1331.2010.03252.x
    1. Shi Z, Chen H, Lian Z, Liu J, Feng H, Zhou H. Factors that impact health-related quality of life in neuromyelitis optica spectrum disorder: anxiety, disability, fatigue and depression. J Neuroimmunol. (2016) 293:54–8. 10.1016/j.jneuroim.2016.02.011
    1. Baweja R, Avasthi A, Chakrabarti S, Prabhakar S. Psychiatric morbidity in patients with transverse myelitis and stroke: a comparison. Indian J Psychiatry (2013) 55:59–62. 10.4103/0019-5545.105509
    1. Moore P, Methley A, Pollard C, Mutch K, Hamid S, Elsone L, et al. . Cognitive and psychiatric comorbidities in neuromyelitis optica. J Neurol Sci. (2016) 360:4–9. 10.1016/j.jns.2015.11.031
    1. Akaishi T, Nakashima I, Misu T, Fujihara K, Aoki M. Depressive state and chronic fatigue in multiple sclerosis and neuromyelitis optica. J Neuroimmunol. (2015) 283:70–3. 10.1016/j.jneuroim.2015.05.007
    1. Pan J, Zhao P, Cai H, Su L, Wood K, Shi FD, et al. . Hypoxemia, sleep disturbances, and depression correlated with fatigue in neuromyelitis optica spectrum disorder. CNS Neurosci Ther. (2015) 21:599–606. 10.1111/cns.12411
    1. Chavarro VS, Mealy MA, Simpson A, Lacheta A, Pache F, Ruprecht K, et al. . Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. (2016) 3:e286. 10.1212/NXI.0000000000000286
    1. Fujimura H. Chapter 21–he Guillain–Barré syndrome. In: Said G, Krarup C. editors. Elsevier Handbook of Clinical Neurology. Toyonaka: Elsevier; (2013). p. 383–402.
    1. Eduardo N-O. Chronic inflammatory demyelinating polyradiculoneuropathy and variants: where we are and where we should go. J Peripher Nerv Syst. (2014) 19:2–13. 10.1111/jns5.12053
    1. van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. (2014) 10:469–82. 10.1038/nrneurol.2014.121
    1. Brousseau K, Arciniegas D, Harris S. Pharmacologic management of anxiety and affective lability during recovery from Guillain-Barré syndrome: some preliminary observations. Neuropsychiatr Dis Treat. (2005) 1:145–9. 10.2147/nedt.1.2.145.61047
    1. Khan F, Pallant JF, Ng L, Bhasker A. Factors associated with long-term functional outcomes and psychological sequelae in Guillain–Barre syndrome. J Neurol. (2010) 257:2024–31. 10.1007/s00415-010-5653-x
    1. Sangroula D, Durrance R, Bhattarai S, Nandakumar T. Neuropsychiatric debut as a presentation of Guillain-Barré Syndrome: an atypical clinical case and literature review. J Clin Neurosci. (2017) 44:245–9. 10.1016/j.jocn.2017.06.041
    1. Tzeng N-S, Chang H-A, Chung C-H, Lin F-H, Yeh C-B, Huang S-Y, et al. . Risk of psychiatric disorders in Guillain-Barre syndrome: a nationwide, population-based, cohort study. J Neurol Sci. (2017) 381:88–94. 10.1016/j.jns.2017.08.022
    1. Kuitwaard K, Bos-Eyssen ME, Blomkwist-Markens PH, van Doorn PA. Recurrences, vaccinations and long-term symptoms in GBS and CIDP. J Peripher Nerv Syst. (2009) 14:310–5. 10.1111/j.1529-8027.2009.00243.x
    1. Weiss H, Rastan V, Müllges W, Wagner RF, Toyka KV. Psychotic symptoms and emotional distress in patients with guillain-barré syndrome. Eur Neurol. (2002) 47:74–8. 10.1159/000047956
    1. Davidson I, Wilson C, Walton T, Brissenden S, Campbell M, McGowan L. What constitutes a ‘good' recovery outcome in post-acute Guillain-Barre syndrome? Eur J Neurol. (2010) 17:677–83. 10.1111/j.1468-1331.2009.02906.x
    1. Merkies ISJ, Kieseier BC. Fatigue, pain, anxiety and depression in guillain-barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. Eur Neurol. (2016) 75:199–206. 10.1159/000445347
    1. Garssen MPJ, Bussmann JBJ, Schmitz PIM, Zandbergen A, Welter TG, Merkies ISJ, et al. . Physical training and fatigue, fitness, and quality of life in Guillain–Barré syndrome and CIDP. Neurology (2004) 63:2393–5. 10.1212/01.WNL.0000148589.87107.9C
    1. Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. (2015) 14:1023–36. 10.1016/S1474-4422(15)00145-3
    1. Sarah H, Johanna R, Ulrike G, Siegfried K, Jana S, Andreas M. Fatigue in myasthenia gravis: risk factors and impact on quality of life. Brain Behav. (2016) 6:e00538 10.1002/brb3.538
    1. Eizaguirre MB, Aguirre F, Yastremiz C, Vanotti S, Villa A. Neuropsychological performance in patients with myasthenia gravis. Medicina (2017) 77:117–20.
    1. Kulaksizoglu IB. Mood and anxiety disorders in patients with myasthenia gravis: aetiology, diagnosis and treatment. CNS Drugs (2007) 21:473. 10.2165/00023210-200721060-00004
    1. Suzuki Y, Utsugisawa K, Suzuki S, Nagane Y, Masuda M, Kabasawa C, et al. . Factors associated with depressive state in patients with myasthenia gravis: a multicentre cross-sectional study. BMJ Open (2011) 1:e000313. 10.1136/bmjopen-2011-000313
    1. Doering S, Henze T, Schüßler G. Coping with illness in myasthenia gravis. Nervenarzt (1993) 64:640–7.
    1. Renoir T, Hasebe K, Gray L. Mind and body: how the health of the body impacts on neuropsychiatry. Front Pharmacol. (2013) 4:158. 10.3389/fphar.2013.00158
    1. Lynch SG, Kroencke DC, Denney DR. The relationship between disability and depression in multiple sclerosis: the role of uncertainty, coping, and hope. Mult Scler J. (2001) 7:411–6. 10.1177/135245850100700611
    1. van der Werf SP, Evers A, Jongen PJ, Bleijenberg G. The role of helplessness as mediator between neurological disability, emotional instability, experienced fatigue and depression in patients with multiple sclerosis. Mult Scler J. (2003) 9:89–94. 10.1191/1352458503ms854oa
    1. Almeida OP, Draper B, Pirkis J, Snowdon J, Lautenschlager NT, Byrne G, et al. . Anxiety, depression, and comorbid anxiety and depression: risk factors and outcome over two years. Int Psychogeriatr. (2012) 24:1622–32. 10.1017/S104161021200107X
    1. Wright CE, Strike PC, Brydon L, Steptoe A. Acute inflammation and negative mood: mediation by cytokine activation. Brain Behav Immun. (2005) 19:345–50. 10.1016/j.bbi.2004.10.003
    1. Gold SM, Irwin MR. Depression and immunity: inflammation and depressive symptoms in multiple sclerosis. Immunol Allergy Clin North Am. (2009) 29:309–20. 10.1016/j.iac.2009.02.008
    1. Haapakoski R, Ebmeier KP, Alenius H, Kivimaki M. Innate and adaptive immunity in the development of depression: an update on current knowledge and technological advances. Prog Neuropsychopharmacol Biol Psychiatry (2016) 66:63–72. 10.1016/j.pnpbp.2015.11.012
    1. Dantzer R. Cytokine-induced sickness behavior: where do we stand? Brain Behav Immun. (2001) 15:7–24. 10.1006/brbi.2000.0613
    1. Gibney SM, McGuinness B, Prendergast C, Harkin A, Connor TJ. Poly I:C-induced activation of the immune response is accompanied by depression and anxiety-like behaviours, kynurenine pathway activation and reduced BDNF expression. Brain Behav Immun. (2013) 28:170–81. 10.1016/j.bbi.2012.11.010
    1. Goodstein R, Ferrell R. Multiple sclerosis–presenting as depressive illness. Dis Nerv Syst. (1977) 38:127–31.
    1. Zorzon M, Zivadinov R, Nasuelli D, Ukmar M, Bratina A, Tommasi M, et al. . Depressive symptoms and MRI changes in multiple sclerosis. Eur J Neurol. (2002) 9:491–6. 10.1046/j.1468-1331.2002.00442.x
    1. Shen Y, Bai L, Gao Y, Cui F, Tan Z, Tao Y, et al. . Depressive symptoms in multiple sclerosis from an in vivo study with TBSS. Biomed Res Int. (2014) 2014:148465. 10.1155/2014/148465
    1. Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct. (2008) 213:93–118. 10.1007/s00429-008-0189-x
    1. Pravata E, Rocca MA, Valsasina P, Riccitelli GC, Gobbi C, Comi G, et al. . Gray matter trophism, cognitive impairment, and depression in patients with multiple sclerosis. Mult Scler. (2017) 23:1864–74. 10.1177/1352458517692886
    1. van Geest Q, Boeschoten RE, Keijzer MJ, Steenwijk MD, Pouwels PJ, Twisk JW, et al. Fronto-limbic disconnection in patients with multiple sclerosis and depression. Mult Scler. (2018). 10.1177/1352458518767051. [Epub ahead of print].
    1. Patten SB, Metz LM. Interferon β1a and depression in secondary progressive MS: data from the SPECTRIMS Trial. Neurology (2002) 59:744. 10.1212/WNL.59.5.744
    1. Patten SB, Barbui C. Drug-induced depression: a systematic review to inform clinical practice. Psychother Psychosom. (2004) 73:207–15. 10.1159/000077739
    1. Reder AT, Oger JF, Kappos L, O'Connor P, Rametta M. Short-term and long-term safety and tolerability of interferon β-1b in multiple sclerosis. Mult Scler Relat Disord. (2014) 3:294–302. 10.1016/j.msard.2013.11.005
    1. Schippling S, O'Connor P, Knappertz V, Pohl C, Bogumil T, Suarez G, et al. . Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. J Neurol. (2016) 263:1418–26. 10.1007/s00415-016-8146-8
    1. Feinstein A. Multiple sclerosis, disease modifying treatments and depression: a critical methodological review. Mult Scler J. (2000) 6:343–8. 10.1177/135245850000600509
    1. Goeb JL, Even C, Nicolas G, Gohier B, Dubas F, Garré JB. Psychiatric side effects of interferon-β in multiple sclerosis. Eur Psychiatry (2006) 21:186–93. 10.1016/j.eurpsy.2005.09.013
    1. Feinstein A. Multiple sclerosis and depression. Mult Scler J. (2011) 17:1276–81. 10.1177/1352458511417835
    1. Mourão AM, Gomez RS, Barbosa LS, Freitas DS, Comini-Frota ER, Kummer A, et al. . Determinants of quality of life in Brazilian patients with myasthenia gravis. Clinics (2016) 71:370–4. 10.6061/clinics/2016(07)03
    1. Patten SB. Exogenous corticosteroids and major depression in the general population. J Psychosom Res. (2000) 49:447–9. 10.1016/S0022-3999(00)00187-2
    1. Twork S, Wiesmeth S, Klewer J, Pöhlau D, Kugler J. Quality of life and life circumstances in German myasthenia gravis patients. Health Qual Life Outcomes (2010) 8:129. 10.1186/1477-7525-8-129
    1. Basta IZ, Pekmezovic TD, Peric SZ, Kisic-Tepavcevic DB, Rakocevic-Stojanovic VM, Stevic ZD, et al. . Assessment of health-related quality of life in patients with myasthenia gravis in Belgrade (Serbia). Neurol Sci. (2012) 33:1375–81. 10.1007/s10072-012-1170-2
    1. Yang Y, Zhang M, Guo J, Ma S, Fan L, Wang X, et al. . Quality of life in 188 patients with myasthenia gravis in China. Int J Neurosci. (2016) 126:455–62. 10.3109/00207454.2015.1038712
    1. Ozakbas S, Turkoglu R, Tamam Y, Terzi M, Taskapilioglu O, Yucesan C, et al. . Prevalence of and risk factors for cognitive impairment in patients with relapsing-remitting multiple sclerosis: multi-center, controlled trial. Mult Scler Relat Disord. (2018) 22:70–6. 10.1016/j.msard.2018.03.009
    1. Landrø NI, Celius EG, Sletvold H. Depressive symptoms account for deficient information processing speed but not for impaired working memory in early phase multiple sclerosis (MS). J Neurol Sci. (2004) 217:211–6. 10.1016/j.jns.2003.10.012
    1. Nunnari D, De Cola MC, D'Aleo G, Rifici C, Russo M, Sessa E, et al. . Impact of depression, fatigue, and global measure of cortical volume on cognitive impairment in multiple sclerosis. Biomed Res Int. (2015) 2015:519785. 10.1155/2015/519785
    1. Krupp LB, Serafin DJ, Christodoulou C. Multiple sclerosis-associated fatigue. Expert Rev Neurother. (2010) 10:1437–47. 10.1586/ern.10.99
    1. Bagert B, Camplair P, Bourdette D. Cognitive dysfunction in multiple sclerosis. CNS Drugs (2002) 16:445–55. 10.2165/00023210-200216070-00002
    1. Mills RJ, Young CA. A medical definition of fatigue in multiple sclerosis. QJM Int J Med. (2008) 101:49–60. 10.1093/qjmed/hcm122
    1. de Vries JM, Hagemans ML, Bussmann JB, van der Ploeg AT, van Doorn PA. Fatigue in neuromuscular disorders: focus on Guillain-Barre syndrome and Pompe disease. Cell Mol Life Sci. (2010) 67:701–13. 10.1007/s00018-009-0184-2
    1. Induruwa I, Constantinescu CS, Gran B. Fatigue in multiple sclerosis–a brief review. J Neurol Sci. (2012) 323:9–15. 10.1016/j.jns.2012.08.007
    1. Azimian M, Shahvarughi-Farahani A, Rahgozar M, Etemadifar M, Nasr Z. Fatigue, depression, and physical impairment in multiple sclerosis. Iran J Neurol. (2014) 13:105–7.
    1. Greeke EE, Chua AS, Healy BC, Rintell DJ, Chitnis T, Glanz BI. Depression and fatigue in patients with multiple sclerosis. J Neurol Sci. (2017) 380:236–41. 10.1016/j.jns.2017.07.047
    1. Corfield EC, Martin NG, Nyholt DR. Co-occurrence and symptomatology of fatigue and depression. Compr Psychiatry (2016) 71:1–10. 10.1016/j.comppsych.2016.08.004

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa